Abaloparatide
- Generic Name
- Abaloparatide
- Brand Names
- Tymlos, Eladynos
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 247062-33-5
- Unique Ingredient Identifier
- AVK0I6HY2U
- Background
Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids and the receptor-activating domain.
...
- Indication
Abaloparatide is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture) or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, abaloparatide reduces the risk...
- Associated Conditions
- Osteoporosis
- Associated Therapies
- -
Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Radius Health, Inc.
- Target Recruit Count
- 22054
- Registration Number
- NCT04974723
- Locations
- 🇺🇸
Radius Health, Boston, Massachusetts, United States
PTH Analog Type II Odontoid Fracture
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- David Lunardini
- Target Recruit Count
- 20
- Registration Number
- NCT04760782
- Locations
- 🇺🇸
University of Vermont Medical Center, Burlington, Vermont, United States
Supracondylar Distal Femur Fractures and Abaloparatide
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Daniel Horwitz
- Registration Number
- NCT04626141
- Locations
- 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 70
- Registration Number
- NCT04467983
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
Abaloparatide Before Total Knee Arthroplasty
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 58
- Registration Number
- NCT04167163
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 96
- Registration Number
- NCT03841058
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 20
- Registration Number
- NCT03746041
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Radius Health, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03710889
- Locations
- 🇺🇸
Panorama Orthopedics & Spine Center, Golden, Colorado, United States
🇺🇸Center for Advanced Research & Education, Gainesville, Georgia, United States
🇺🇸Harvard Medical School, Boston, Massachusetts, United States
Effect of Abaloparatide on Lumbar Disc Degeneration
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT03708926
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Radius Health, Inc.
- Target Recruit Count
- 228
- Registration Number
- NCT03512262
- Locations
- 🇺🇸
Meridian Clinical Research, Savannah, Georgia, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.